Prognosis
Regeneron Covid-19 Therapy Reduces Viral Load, Need for Care
- Results have been shared with regulators evaluating clearance
- Company weighing change to dosing that could extend supply
This article is for subscribers only.
Regeneron Pharmaceuticals Inc. said data from a late-stage clinical trial suggest that its antibody cocktail therapy for Covid-19 significantly reduces virus levels and the need for further medical care.
The results offer another encouraging signal in the race to find treatments for the deadly virus. Patients outside the hospital who got the therapy were 57% less likely to need medical care later, with 2.8% of those given the antibody and 6.5% of those on placebo seeing a health-care worker within 29 days.